Your browser doesn't support javascript.
loading
Epidermal growth factor receptor association with ß1-adrenergic receptor is mediated via its juxtamembrane domain.
Patwa, Viren; Guo, Shuchi; Carter, Rhonda L; Kraus, Lindsay; Einspahr, Jeanette; Teplitsky, David; Sabri, Abdelkarim; Tilley, Douglas G.
Affiliation
  • Patwa V; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Guo S; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Carter RL; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Kraus L; Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Einspahr J; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Teplitsky D; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Sabri A; Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Tilley DG; Center for Translational Medicine, Temple University, Philadelphia, PA 19140, USA. Electronic address: douglas.tilley@temple.edu.
Cell Signal ; 78: 109846, 2021 02.
Article in En | MEDLINE | ID: mdl-33238186
ABSTRACT
ß1-adrenergic receptor (ß1AR)-mediated transactivation of epidermal growth factor receptor (EGFR) engages downstream signaling events that impact numerous cellular processes including growth and survival. While association of these receptors has been shown to occur basally and be important for relaying transactivation-specific intracellular events, the mechanism by which they do so is unclear and elucidation of which would aid in understanding the consequence of disrupting their interaction. Using fluorescence resonance energy transfer (FRET) and immunoprecipitation (IP) analyses, we evaluated the impact of C-terminal truncations of EGFR on its ability to associate with ß1AR. While loss of the last 230 amino acid C-terminal phosphotyrosine-rich domain did not disrupt the ability of EGFR to associate with ß1AR, truncation of the entire intracellular domain of EGFR resulted in almost complete loss of its interaction with ß1AR, suggesting that either the kinase domain or juxtamembrane domain (JMD) may be required for this association. Treatment with the EGFR antagonist gefitinib did not prevent ß1AR-EGFR association, however, treatment with a palmitoylated peptide encoding the first 20 amino acids of the JMD domain (JMD-A) disrupted ß1AR-EGFR association over time and prevented ß1AR-mediated ERK1/2 phosphorylation, both in general and specifically in association with EGFR. Conversely, neither a mutated JMD-A peptide nor a palmitoylated peptide fragment consisting of the subsequent 18 amino acids of the JMD domain (JMD-B) were capable of doing so. Altogether, the proximal region of the JMD of EGFR is responsible for its association with ß1AR, and its disruption prevents ß1AR-mediated transactivation, thus providing a new tool to study the functional consequences of disrupting ß1AR-EGFR downstream signaling.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Receptors, Adrenergic, beta-1 Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Cell Signal Year: 2021 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Receptors, Adrenergic, beta-1 Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Cell Signal Year: 2021 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM